168 results

• GLP-1 Vision Loss Risks Extend Beyond Type 2 Diabetics and Ozempic Users, Study Warns

  August 6, 2025

  Irvin Jackson

  New research suggests that vision problems are not restricted to just Ozempic, but may be a risk faced by all GLP-1 medication users.

• Study Finds Ketoacidosis Risks from Side Effects of Invokana, Jardiance, Similar Diabetes Drugs

  May 12, 2025

  Irvin Jackson

  Diabetes drugs like Invokana may reduce the risk of kidney injury and death after surgery, but may also increase the risk of a form of diabetic ketoacidosis that is hard to detect.

• Court Urged To Reject Motion To Dismiss Lawsuits Over Ozempic, Mounjaro Gastrointestinal Risks

  March 21, 2025

  Irvin Jackson

  Pushing back against a motion to dismiss, plaintiffs involved in GLP-1 lawsuits say GLP-1 manufacturers intentionally misled the medical community and patients regarding the safety of the diabetes and weight loss drugs.

• GLP-1 Manufacturers Argue Gastroparesis Lawsuits Should Require Contemporaneous Diagnostic Testing

  March 17, 2025

  Irvin Jackson

  Eli Lilly has filed a motion calling for a federal judge to put in place specific requirements for establishing a gastroparesis diagnosis in stomach paralysis lawsuits filed against the makers of Mounjaro, Ozempic and other GLP-1 medications.

• Study Suggests There May Not Be a Link Between Ozempic, Mounjaro and Post-Surgery Aspiration Pneumonia

  March 12, 2025

  Irvin Jackson

  New findings appear to contradict warnings that GLP-1 drugs, like Ozempic and Mounjaro, can increase the risk of post-surgical aspiration due to a lack of gastric emptying.

• GLP-1 Drug Prescriptions Have Doubled in Recent Years, But Many Users Quit Soon After Starting

  February 10, 2025

  Irvin Jackson

  Two new studies mark the rapid rise in Ozempic, Wegovy, Zepbound and other GLP-1 medication prescriptions in recent years, but warns that a variety of factors, including side effects, age, income and weight loss, often make new users quit within a year.

• GLP-1 Lawsuit Defendants Filed Motion To Dismiss Most Claims in Plaintiffs’ Master Complaint

  January 31, 2025

  Irvin Jackson

  Two major drug manufacturers are asking a federal judge to dismiss most claims presented in GLP-1 lawsuits, which allege that side effects of Ozempic, Mounjaro and similar drugs cause severe gastrointestinal side effects.

• Increased GLP-1 Thyroid Cancer Risks May Be Product of More Intense Screening, Study Finds

  January 29, 2025

  Irvin Jackson

  The findings of a new study suggest that an apparent association between GLP-1 medications and thyroid cancer may be due to more intensive patient screening, and not a side effect of the drugs themselves.

• Evidentiary Hearing for “Cross Cutting” Ozempic Lawsuit Causation Issues Scheduled for May 2025

  January 3, 2025

  Irvin Jackson

  A federal judge has scheduled a hearing in May to review evidence linking Ozempic and similar drugs to gastrointestinal problems, such as gastroparesis and intestinal obstruction.

• MDL Judge Schedules Ozempic Lawsuit Status Conferences Throughout 2025

  December 5, 2024

  Irvin Jackson

  With the first Ozempic lawsuit bellwether trials not expected to begin until at least late 2026 or early 2027, the court will address motions to dismiss and other “cross cutting” issues in 2025.